AtriCure, Inc. — News

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-23 21:40:26

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-07-23 20:01:06

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.

zacks.com - 2026-07-23 18:27:13

AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.

marketbeat.com - 2026-07-23 18:07:47

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu.

businesswire.com - 2026-07-23 16:01:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listeni.

businesswire.com - 2026-07-02 08:00:00

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a

gurufocus.com - 2026-07-02 08:00:00

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com - 2026-06-19 08:41:05

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

zacks.com - 2026-06-11 10:47:23

AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 11:52:20

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a

gurufocus.com - 2026-05-27 08:00:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested.

businesswire.com - 2026-05-27 08:00:00

AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 15:30:48

AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.

marketbeat.com - 2026-05-12 15:10:52

AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 02:11:14

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-05-05 21:31:31

AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.

zacks.com - 2026-05-05 18:16:21

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. “Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined execution and increased adoption of our innovative products,” said Michael Carrel, President and Chief Executive Officer.

businesswire.com - 2026-05-05 16:01:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested par.

businesswire.com - 2026-04-28 08:00:00

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

seekingalpha.com - 2026-04-26 22:10:00